Becton Dickinson & Co - BDX STOCK NEWS

BD (Becton, Dickinson and Company) has appointed Michelle Quinn as acting general counsel effective February 3, 2023. She succeeds Samrat Khichi, who is leaving for a new opportunity. Quinn has been with BD since 2019, serving as senior vice president and chief ethics officer. She will lead BD's Law Group and is expected to contribute to the company’s 2025 strategy. In related changes, Ami Simunovich and Chris DelOrefice will oversee new responsibilities, reporting directly to BD’s CEO, Tom Polen.

BD (Becton, Dickinson and Company) will release its financial results for the first quarter of fiscal year 2023 on February 2, 2023, at 6:30 a.m. ET. The results will cover the quarter ending on December 31, 2022, and will be available on their investor relations website. Following the release, management will host an audio webcast at 8 a.m. ET on the same day to discuss the financial results and company strategy. BD is recognized as a leading global medical technology company committed to enhancing healthcare through innovative solutions.

BD (Becton, Dickinson and Company) released survey results showing a significant knowledge gap among U.S. women about cervical cancer causes and prevention. Conducted by Harris Poll, 71% of women reported delaying Pap tests, with minority groups disproportionately affected. Despite 91% claiming general health knowledge, many lack understanding of cervical cancer screenings, with 67% unaware that HPV causes most cervical cancers. The survey indicates a need for improved education and access to self-collection kits as 79% of women show interest in them.

BD (Becton, Dickinson and Company) announced its participation in the 41^st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 pm Eastern Time. The live webcast will be available on the BD investor relations website, with a replay accessible post-event. BD is a global leader in medical technology, committed to advancing health care through innovative solutions and technology, showcasing its presence in numerous countries and focus on improving care delivery.

BD (Becton, Dickinson and Company) (NYSE: BDX) will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022, at 8:00 am Eastern Time. The presentation will be accessible via BD's investor relations website, with a replay available post-event.

BD is a leading global medical technology firm focused on enhancing health through innovative technologies and solutions. With a workforce of 77,000, BD partners globally to tackle health challenges and improve care delivery.

BD (Becton, Dickinson and Company) reported Q4 revenue of $4.8 billion, down 1.8% year-over-year, but up 2.3% on a currency-neutral basis. For FY22, revenue was $18.9 billion, also decreasing by 1.4%. Q4 GAAP diluted EPS rose 100% to $0.92, while adjusted EPS increased 27.9% to $2.75. The company maintains a robust outlook, projecting FY23 revenue between $18.6 billion and $18.8 billion with adjusted diluted EPS expected to be $11.85 to $12.10. BD also marked its 51st consecutive year of dividend increases, raising it by 4.6%. The company continues to execute on its BD 2025 strategy.

The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per share, marking a 4.6% increase from the prior quarter. This dividend will be paid on Dec. 30, 2022, to those on record by Dec. 9, 2022. For the fiscal year 2023, the projected annual dividend rate is $3.64 per share. This represents the 51st consecutive year of dividend increases, reaffirming BD’s status as a component of the S&P 500 Dividend Aristocrats Index.

BD (Becton, Dickinson and Company) (NYSE: BDX) has entered a co-exclusive commercial agreement with Magnolia Medical Technologies to reduce blood culture contamination in U.S. hospitals. The collaboration will promote Magnolia Medical's Steripath® Initial Specimen Diversion Device®, which is FDA-cleared to enhance testing accuracy for sepsis. This device meets the new 1% blood culture contamination guideline set by the CDC. Clinical studies support its effectiveness, with many hospitals adopting it to improve patient outcomes and reduce healthcare costs associated with contamination.